Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Very few people get to invent a new language that is heard by millions: DW talked to linguist Paul Frommer about how he ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

The story of a cancer-fighting molecule that took half a century to build is really a story about how slow, stubborn ...

New grading scales for ocular adverse events in oncology improve clarity and provide drug-dose-modification recommendations, ...

Kyongbo Pharmaceutical, a subsidiary of Chong Kun Dang, said on the 15th that it recently established an antibody-drug conjugate (ADC) research center in Yongin to produce preclinical research samples ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...